Giaccone, Giuseppe

Publications

Sort by

Co-Author Network

selected publications

Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials. Expert opinion on investigational drugs. 2022 Review GET IT
Times cited: 3
Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials: A Systematic Review and Meta-analysis. JAMA network open. 2022 Review GET IT
Times cited: 4
Sex and cancer immunotherapy: Current understanding and challenges. Cancer cell. 2022 Academic Article GET IT
Times cited: 6
The regulation of CD73 in non-small cell lung cancer. European journal of cancer (Oxford, England : 1990). 2022 Academic Article GET IT
Times cited: 6
Impact of Baseline Clinical Biomarkers on Treatment Outcomes in Patients With Advanced NSCLC Receiving First-line Pembrolizumab-Based Therapy. Clinical lung cancer. 2022 Academic Article GET IT
Times cited: 2
The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Unresolved Issues to be Addressed for the Next Ninth Edition of the TNM Classification of Malignant Tumors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2022 Academic Article GET IT
Times cited: 2
Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine. British journal of cancer. 2021 Academic Article GET IT
Times cited: 2
Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers. Lung cancer (Amsterdam, Netherlands). 2021 Academic Article GET IT
Times cited: 4
PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine. Journal for immunotherapy of cancer. 2021 Academic Article GET IT
Times cited: 4
A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. Frontiers in oncology. 2021 Academic Article GET IT
Times cited: 102
Molecular predictors of response to pembrolizumab in thymic carcinoma. Cell reports. Medicine. 2021 Academic Article GET IT
Times cited: 16
Lung Cancer Stage Shift as a Result of COVID-19 Lockdowns in New York City, a Brief Report. Clinical lung cancer. 2021 Academic Article GET IT
Times cited: 9
Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials. ESMO open. 2021 Review GET IT
Times cited: 18
Cardiomyocyte-specific circulating cell-free methylated DNA in esophageal cancer patients treated with chemoradiation. Gastrointestinal disorders (Basel, Switzerland). 2021 Academic Article GET IT
Times cited: 1
Arginase Pathway Markers of Immune-Microenvironment in Thymic Epithelial Tumors and Small Cell Lung Cancer. Clinical lung cancer. 2021 Academic Article GET IT
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2021 Academic Article GET IT
Times cited: 46
A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression. Frontiers in oncology. 2021 Review GET IT
Times cited: 71
Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 28
The Prognostic Value of Non-Predominant Micropapillary Pattern in a Large Cohort of Resected Invasive Lung Adenocarcinoma Measuring ≤3 cm. Frontiers in oncology. 2021 Academic Article GET IT
Times cited: 52
Challenges in Diversity, Equity, and Inclusion in Research and Clinical Oncology. Frontiers in oncology. 2021 Academic Article GET IT
Times cited: 5
Small cell lung cancer: a slightly less orphan disease after immunotherapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2021 Review GET IT
Times cited: 29
In Memory of Professor John Gordon McVie: Bringing People Together 13 January 1945 - 20 January 2021. Frontiers in oncology. 2021 Academic Article GET IT
Thymic malignancies treated with active scanning proton beam radiation and Monte Carlo planning: early clinical experience. Acta oncologica (Stockholm, Sweden). 2021 Letter GET IT
Times cited: 2
Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation. Molecular oncology. 2021 Academic Article GET IT
Times cited: 10
Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2020 Academic Article GET IT
Times cited: 26
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. The New England journal of medicine. 2020 Academic Article GET IT
Times cited: 656
Genomic characteristics in Chinese non-small cell lung cancer patients and its value in prediction of postoperative prognosis. Translational lung cancer research. 2020 Academic Article GET IT
Times cited: 50
Downregulation of CYLD promotes IFN-γ mediated PD-L1 expression in thymic epithelial tumors. Lung cancer (Amsterdam, Netherlands). 2020 Academic Article GET IT
Times cited: 10
Metastatic intracranial solitary fibrous tumors/hemangiopericytomas: description of two cases with radically different behaviors and review of the literature. Anti-cancer drugs. 2020 Review GET IT
Times cited: 2
Phase I study of the ¹⁷⁷Lu-DOTA⁰-Tyr³-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. Journal for immunotherapy of cancer. 2020 Academic Article GET IT
Times cited: 31
LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers. Cancer letters. 2020 Academic Article GET IT
Times cited: 45
Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2020 Academic Article GET IT
Times cited: 3
Thymic epithelial tumors: From biology to treatment. Cancer treatment reviews. 2020 Review GET IT
Times cited: 41
Mutant GTF2I induces cell transformation and metabolic alterations in thymic epithelial cells. Cell death and differentiation. 2020 Academic Article GET IT
Times cited: 14
Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA)_n Repeat Polymorphism: Potential Clinical Consequences of Genotyping Errors?. International journal of molecular sciences. 2020 Academic Article GET IT
Times cited: 4
Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH. Cell death and differentiation. 2020 Academic Article GET IT
Times cited: 34
Effectiveness of intensive clinical and radiological follow-up in patients with surgically resected NSCLC. Analysis of 2661 patients from the prospective MAGRIT trial. European journal of cancer (Oxford, England : 1990). 2019 Academic Article GET IT
Times cited: 7
The International Association for the Study of Lung Cancer Thymic Tumors Staging Project: The Impact of the Eighth Edition of the Union for International Cancer Control and American Joint Committee on Cancer TNM Stage Classification of Thymic Tumors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Academic Article GET IT
Times cited: 35
Publication Rate and Characteristics of Lung Cancer Clinical Trials. JAMA network open. 2019 Academic Article GET IT
Times cited: 3
Author's Reply. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Letter GET IT
Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives. Drug design, development and therapy. 2019 Review GET IT
Times cited: 28
Best practices and guidelines for the management of thymic epithelial tumors. Mediastinum (Hong Kong, China). 2019 Editorial Article GET IT
Times cited: 1
A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer. Translational lung cancer research. 2019 Academic Article GET IT
Times cited: 108
Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2019 Academic Article GET IT
Times cited: 16
TPP1 OB-fold domain protein suppresses cell proliferation and induces cell apoptosis by inhibiting telomerase recruitment to telomeres in human lung cancer cells. Journal of cancer research and clinical oncology. 2019 Academic Article GET IT
Times cited: 4
Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer. PloS one. 2019 Academic Article GET IT
Times cited: 6
Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Academic Article GET IT
Times cited: 29
Surgical Resection of SCLC: Prognostic Factors and the Tumor Microenvironment. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Academic Article GET IT
Times cited: 49
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. European journal of cancer (Oxford, England : 1990). 2019 Academic Article GET IT
Times cited: 43
Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC. PloS one. 2018 Academic Article GET IT
Times cited: 13
Reprint of: Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Cancer genetics. 2018 Academic Article GET IT
Times cited: 4
Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Review GET IT
Times cited: 17
Dramatic Response to Sequential BRAF Inhibition in BRAF V600E-Mutant Metastatic Lung Adenocarcinoma. JCO precision oncology. 2018 Academic Article GET IT
What Can We Learn From the French Experience in Systemic Treatment of Thymic Epithelial Tumors?. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018 Editorial Article GET IT
Times cited: 1
Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer. Oncogene. 2018 Academic Article GET IT
Times cited: 28
Understanding molecular diagnostic technology in oncology through the lens of lung cancer. Discovery medicine. 2018 Review GET IT
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. European journal of cancer (Oxford, England : 1990). 2018 Academic Article GET IT
Times cited: 38
Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity. European journal of cancer (Oxford, England : 1990). 2018 Academic Article GET IT
Times cited: 22
Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung. Anti-cancer drugs. 2018 Academic Article GET IT
Times cited: 32
Precision oncology in non-small-cell lung cancer: opportunities and challenges. Nature reviews. Clinical oncology. 2018 Academic Article GET IT
Times cited: 16
30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). ESMO open. 2018 Review GET IT
Times cited: 1080
Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer. Cancer chemotherapy and pharmacology. 2018 Academic Article GET IT
Times cited: 6
The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. Cell death and differentiation. 2018 Academic Article GET IT
Times cited: 64
C-MET inhibitors for advanced non-small cell lung cancer. Expert opinion on investigational drugs. 2018 Review GET IT
Times cited: 72
Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline. 2018 GET IT
Times cited: 46
A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation. Clinical lung cancer. 2018 Academic Article GET IT
Times cited: 17
A Phase Ib/II Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung Cancer. Frontiers in oncology. 2018 Academic Article GET IT
Times cited: 39
Eighth Edition Staging of Thoracic Malignancies: Implications for the Reporting Pathologist. Archives of pathology & laboratory medicine. 2018 Review GET IT
Times cited: 15
The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018 Academic Article GET IT
Times cited: 33
The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer cell. 2018 Academic Article GET IT
Times cited: 206
A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies. Cancer chemotherapy and pharmacology. 2018 Academic Article GET IT
Times cited: 56
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. The Lancet. Oncology. 2018 Academic Article GET IT
Times cited: 229
High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2017 Academic Article GET IT
Times cited: 18
MEK inhibitors under development for treatment of non-small-cell lung cancer. Expert opinion on investigational drugs. 2017 Review GET IT
Times cited: 49
An endogenous DNA adduct as a prognostic biomarker for hepatocarcinogenesis and its prevention by Theaphenon E in mice. Hepatology (Baltimore, Md.). 2017 Academic Article GET IT
Times cited: 11
Combined Small Cell Carcinoma of the Lung: Is It a Single Entity?. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017 Academic Article GET IT
Times cited: 38
Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients. Journal of oncology practice. 2017 Comment GET IT
Times cited: 3
A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 25
Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Cancer genetics. 2017 Academic Article GET IT
Times cited: 42
Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. Lung cancer (Amsterdam, Netherlands). 2017 Academic Article GET IT
Times cited: 8
Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors. Cancer research. 2017 Academic Article GET IT
Times cited: 24
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 454
Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations. Scientific reports. 2017 Academic Article GET IT
Times cited: 52
The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017 Academic Article GET IT
Times cited: 273
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 165
Ganetespib for small cell lung cancer. Expert opinion on investigational drugs. 2016 Review GET IT
Times cited: 4
Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design. Annals of translational medicine. 2016 Editorial Article GET IT
Times cited: 73
Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. 2016 GET IT
Times cited: 43
Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response. 2016 GET IT
Times cited: 18
Expression of mesothelin in thymic carcinoma and its potential therapeutic significance. Lung cancer (Amsterdam, Netherlands). 2016 Academic Article GET IT
Times cited: 15
Lung cancer: First-line immunotherapy in lung cancer - taking the first step. Nature reviews. Clinical oncology. 2016 Comment GET IT
Times cited: 4
CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma. Oncotarget. 2016 Academic Article GET IT
Times cited: 11
PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Academic Article GET IT
Times cited: 33
The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Review GET IT
Times cited: 437
Novel approaches in cancer immunotherapy. Discovery medicine. 2016 Academic Article GET IT
Times cited: 20
EGFR Mutations in Latinos From the United States and Latin America. Journal of global oncology. 2016 Academic Article GET IT
Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Academic Article GET IT
Times cited: 48
Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Review GET IT
Times cited: 130
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Academic Article GET IT
Times cited: 74
Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. Journal of oncology practice. 2016 Academic Article GET IT
Times cited: 20
Novel Treatments for Thymoma and Thymic Carcinoma. Frontiers in oncology. 2015 Academic Article GET IT
Times cited: 9
EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer. Molecular oncology. 2015 Academic Article GET IT
Times cited: 27
Impact of an Interactive On-line Tool on Therapeutic Decision-Making for Patients with Advanced Non-Small-Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Academic Article GET IT
Times cited: 2
Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 224
Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Review GET IT
Times cited: 47
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. 2015 GET IT
Times cited: 409
A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. European journal of cancer (Oxford, England : 1990). 2015 Academic Article GET IT
Times cited: 171
Why has active immunotherapy not worked in lung cancer?. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Review GET IT
Times cited: 37
Reply to A. Stenzinger et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Letter GET IT
Alterations of immune cell subsets in relapsed, thymoma-associated minimal change disease: A case report. Oncology letters. 2015 Academic Article GET IT
Times cited: 12
Trends and Characteristics of Young Non-Small Cell Lung Cancer Patients in the United States. Frontiers in oncology. 2015 Academic Article GET IT
Times cited: 63
Refining the treatment of NSCLC according to histological and molecular subtypes. Nature reviews. Clinical oncology. 2015 Review GET IT
Times cited: 226
High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. Oncotarget. 2015 Academic Article GET IT
Times cited: 60
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 132
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Academic Article GET IT
Times cited: 225
Next-Generation Sequencing: Targeting Targeted Therapies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Comment GET IT
Times cited: 10
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 182
Multiorgan autoimmune manifestations associated with thymoma. 2015 GET IT
Times cited: 8
LAMC2 enhances the metastatic potential of lung adenocarcinoma. Cell death and differentiation. 2015 Academic Article GET IT
Times cited: 67
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. The Lancet. Oncology. 2015 Academic Article GET IT
Times cited: 189
Classification of current anticancer immunotherapies. Oncotarget. 2014 Review GET IT
Times cited: 340
Mutations of epigenetic regulatory genes are common in thymic carcinomas. Scientific reports. 2014 Academic Article GET IT
Times cited: 93
Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Review GET IT
Times cited: 49
Genomics-based early-phase clinical trials in oncology: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. European journal of cancer (Oxford, England : 1990). 2014 Academic Article GET IT
Times cited: 6
A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 72
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Academic Article GET IT
Times cited: 276
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Academic Article GET IT
Times cited: 91
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the T Component for the forthcoming (8th) edition of the TNM classification of malignant tumors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Academic Article GET IT
Times cited: 124
The ITMIG/IASLC Thymic Epithelial Tumors Staging Project: A Proposed Lymph Node Map for Thymic Epithelial Tumors in the Forthcoming 8th Edition of the TNM Classification of Malignant Tumors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Academic Article GET IT
Times cited: 106
A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nature genetics. 2014 Academic Article GET IT
Times cited: 161
CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. The Journal of clinical investigation. 2014 Academic Article GET IT
Times cited: 79
Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. Journal of molecular medicine (Berlin, Germany). 2014 Review GET IT
Times cited: 52
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014 Academic Article GET IT
Times cited: 1259
Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Academic Article GET IT
Times cited: 29
Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Academic Article GET IT
Times cited: 31
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer. 2014 Academic Article GET IT
Times cited: 120
Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Review GET IT
Times cited: 74
Lung cancer in 2013: Refining standard practice and admitting uncertainty. Nature reviews. Clinical oncology. 2014 Review GET IT
Times cited: 7
CYB5A and autophagy-mediated cell death in pancreatic cancer. Autophagy. 2014 Academic Article GET IT
Times cited: 7
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. The Lancet. Oncology. 2014 Academic Article GET IT
Times cited: 98
Emerging protein kinase inhibitors for non-small cell lung cancer. Expert opinion on emerging drugs. 2013 Review GET IT
Times cited: 20
Role of CYB5A in pancreatic cancer prognosis and autophagy modulation. Journal of the National Cancer Institute. 2013 Academic Article GET IT
Times cited: 48
The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Academic Article GET IT
Times cited: 66
HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer. Oncogene. 2013 Academic Article GET IT
Times cited: 40
The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 24
Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy. Frontiers in oncology. 2013 Review GET IT
Times cited: 825
Acute autoimmune hepatitis, myositis, and myasthenic crisis in a patient with thymoma. 2013 GET IT
Times cited: 12
Thymomas: the need for prospective studies. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Editorial Article GET IT
Times cited: 1
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Academic Article GET IT
Times cited: 46
Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer. Molecular cancer therapeutics. 2013 Academic Article GET IT
Times cited: 25
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. The Lancet. Oncology. 2013 Academic Article GET IT
Times cited: 436
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Academic Article GET IT
Times cited: 117
Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer. The oncologist. 2013 Academic Article GET IT
Times cited: 8
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. 2013 GET IT
Times cited: 663
Whole genome and transcriptome sequencing of a B3 thymoma. 2013 GET IT
Times cited: 23
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. 2013 GET IT
Times cited: 375
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. 2013 GET IT
Times cited: 369
"Pseudocavitation" in thymic carcinoma during treatment with sunitinib. 2013 GET IT
Times cited: 1
Response to: intrapulmonary lymph node retrieval. Translational lung cancer research. 2013 Academic Article GET IT
Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors. Cancer science. 2013 Academic Article GET IT
Times cited: 43
Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations. 2013 GET IT
Times cited: 17
Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 24
Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. European journal of cancer (Oxford, England : 1990). 2013 Academic Article GET IT
Times cited: 10
18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 23
Characterization and management of cardiac involvement of thymic epithelial tumors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Academic Article GET IT
Times cited: 13
Dacomitinib, a new therapy for the treatment of non-small cell lung cancer. Expert opinion on pharmacotherapy. 2013 Review GET IT
Times cited: 31
Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors. Current pharmaceutical design. 2013 Academic Article GET IT
Reproducibility of the WHO classification of thymomas: practical implications. Lung cancer (Amsterdam, Netherlands). 2012 Academic Article GET IT
Times cited: 37
Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 2012 Academic Article GET IT
Times cited: 46
Intrapulmonary lymph node retrieval: unclear benefit for aggressive pathologic dissection. Translational lung cancer research. 2012 Academic Article GET IT
Times cited: 5
Semiautomated laser capture microdissection of lung adenocarcinoma cytology samples. Acta cytologica. 2012 Academic Article GET IT
Times cited: 16
From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Review GET IT
Times cited: 55
Hepatoid carcinoma of the lung with anaplastic lymphoma kinase gene rearrangement. 2012 GET IT
Times cited: 18
Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy. Current molecular medicine. 2012 Review GET IT
Times cited: 38
Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 2012 Academic Article GET IT
Times cited: 229
Response to crizotinib in ROS1-rearranged non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Letter GET IT
Times cited: 20
Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. Cell death & disease. 2012 Academic Article GET IT
Times cited: 46
HER2 mutations in non-small-cell lung cancer can be continually targeted. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Letter GET IT
Times cited: 22
Neuroendocrine ACTH-producing tumor of the thymus--experience with 12 patients over 25 years. The Journal of clinical endocrinology and metabolism. 2012 Academic Article GET IT
Times cited: 52
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 415
NUT rearrangement is uncommon in human thymic epithelial tumors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012 Academic Article GET IT
Times cited: 16
Tyrosine kinase inhibitors in lung cancer. Hematology/oncology clinics of North America. 2012 Review GET IT
Times cited: 28
Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors. Current opinion in oncology. 2012 Review GET IT
Times cited: 29
A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 137
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 117
Drug development: portals of discovery. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 37
EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2011 Academic Article GET IT
Times cited: 66
DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens. Current drug metabolism. 2011 Review GET IT
Times cited: 8
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. Journal of oncology practice. 2011 Academic Article GET IT
Times cited: 45
Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 21
Thymic malignancies: from clinical management to targeted therapies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Review GET IT
Times cited: 111
Targeted agents: how to select the winners in preclinical and early clinical studies?. European journal of cancer (Oxford, England : 1990). 2011 Review GET IT
Times cited: 28
Image microarrays (IMA): Digital pathology's missing tool. Journal of pathology informatics. 2011 Academic Article GET IT
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. Cell cycle (Georgetown, Tex.). 2011 Academic Article GET IT
Times cited: 45
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 108
Grand challenges in oncology. Frontiers in oncology. 2011 Academic Article GET IT
Times cited: 3631
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. 2011 GET IT
Times cited: 255
Glioblastoma-induced inhibition of Langerhans cell differentiation from CD34(+) precursors is mediated by IL-6 but unaffected by JAK2/STAT3 inhibition. Immunotherapy. 2011 Academic Article GET IT
Times cited: 7
A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 117
Population pharmacokinetic analysis of sorafenib in patients with solid tumours. British journal of clinical pharmacology. 2011 Academic Article GET IT
Times cited: 114
Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Academic Article GET IT
Times cited: 13
MicroRNA expression and clinical outcome of small cell lung cancer. PloS one. 2011 Academic Article GET IT
Times cited: 66
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 90
Challenges in cancer molecular targets and therapeutics. Frontiers in oncology. 2011 Academic Article GET IT
Times cited: 713
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 155
American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 456
Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies. Cancer chemotherapy and pharmacology. 2011 Academic Article GET IT
Times cited: 25
Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 22
Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer treatment reviews. 2011 Review GET IT
Times cited: 87
Chemotherapy for thymic tumors: induction, consolidation, palliation. Thoracic surgery clinics. 2011 Review GET IT
Times cited: 28
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics. 2011 Academic Article GET IT
Times cited: 59
Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 54
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 60
Lung cancer vaccines. Cancer journal (Sudbury, Mass.). 2011 Review GET IT
Times cited: 42
Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry. 2010 GET IT
Times cited: 35
STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Current opinion in investigational drugs (London, England : 2000). 2010 Review GET IT
Times cited: 111
Archival fine-needle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling. The Journal of molecular diagnostics : JMD. 2010 Academic Article GET IT
Times cited: 88
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer research. 2010 Academic Article GET IT
Times cited: 120
Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer. 2010 Academic Article GET IT
Times cited: 46
Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A. International journal of oncology. 2010 Academic Article GET IT
Times cited: 15
Epithelial tumors of the thymic gland are rare malignancies. Foreword. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010 Academic Article GET IT
Targeted therapy for advanced thymic tumors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010 Review GET IT
Times cited: 23
Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2010 Academic Article GET IT
Times cited: 1
Expression and mutational status of c-kit in thymic epithelial tumors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010 Academic Article GET IT
Times cited: 52
The role of talactoferrin alpha in the treatment of non-small cell lung cancer. Expert opinion on biological therapy. 2010 Review GET IT
Times cited: 19
Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood. 2010 Academic Article GET IT
Times cited: 114
Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab. 2010 GET IT
Times cited: 38
Targeting the dynamic HSP90 complex in cancer. Nature reviews. Cancer. 2010 Review GET IT
Times cited: 1167
A population-based assessment of mortality and morbidity patterns among patients with thymoma. International journal of cancer. 2010 Academic Article GET IT
Times cited: 45
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. Journal of experimental & clinical cancer research : CR. 2010 Academic Article GET IT
Times cited: 91
Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proceedings of the National Academy of Sciences of the United States of America. 2010 Academic Article GET IT
Times cited: 107
Phase I trial of SU14813 in patients with advanced solid malignancies. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Academic Article GET IT
Times cited: 24
Acupuncture treatment for persistent hiccups in patients with cancer. Journal of alternative and complementary medicine (New York, N.Y.). 2010 Academic Article GET IT
Times cited: 23
Targeted therapies: Importance of patient selection for EGFR TKIs in lung cancer. Nature reviews. Clinical oncology. 2010 Article GET IT
Times cited: 7
Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. Clinical lung cancer. 2010 Review GET IT
Times cited: 30
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. The Lancet. Oncology. 2010 Academic Article GET IT
Times cited: 1151
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PloS one. 2010 Academic Article GET IT
Times cited: 268
Thymoma-associated paraneoplastic polymyositis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Letter GET IT
Times cited: 8
Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells. European journal of pharmacology. 2010 Academic Article GET IT
Times cited: 46
A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 79
[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2010 Academic Article GET IT
Times cited: 12
Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Molecular cancer therapeutics. 2010 Academic Article GET IT
Times cited: 64
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. European journal of cancer (Oxford, England : 1990). 2010 Academic Article GET IT
Times cited: 53
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. Journal of oncology practice. 2010 Academic Article GET IT
Times cited: 666
International thymic malignancy interest group. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010 Editorial Article GET IT
Times cited: 8
Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC). Current drug targets. 2010 Review GET IT
Times cited: 16
The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone. Trials. 2009 Academic Article GET IT
Times cited: 53
Antiangiogenesis induced tumor cavitation in lung cancer. 2009 GET IT
Times cited: 1
Small-molecule inhibitors of the human epidermal receptor family. Expert opinion on investigational drugs. 2009 Review GET IT
Times cited: 24
The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer. Current opinion in investigational drugs (London, England : 2000). 2009 Review GET IT
Times cited: 31
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. European journal of cancer (Oxford, England : 1990). 2009 Academic Article GET IT
Times cited: 100
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. 2009 GET IT
Times cited: 666
Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2009 Academic Article GET IT
Times cited: 28
Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2009 Academic Article GET IT
Times cited: 93
Plantar erythrodysesthesia with bullous otitis externa, toxicities from sorafenib: a case report. 2009 GET IT
Times cited: 14
Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling. Proteome science. 2009 Academic Article GET IT
Times cited: 681
Met amplification and HSP90 inhibitors. Cell cycle (Georgetown, Tex.). 2009 Comment GET IT
Times cited: 2
Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 205
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 356
Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells. Lung cancer (Amsterdam, Netherlands). 2009 Academic Article GET IT
Times cited: 34
A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. European journal of cancer (Oxford, England : 1990). 2009 Academic Article GET IT
Times cited: 17
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Annals of oncology : official journal of the European Society for Medical Oncology. 2009 Academic Article GET IT
Times cited: 149
Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. BMC cancer. 2009 Academic Article GET IT
Times cited: 74
Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2009 Academic Article GET IT
Times cited: 23
Next generation oncology drug development: opportunities and challenges. Nature reviews. Clinical oncology. 2009 Review GET IT
Times cited: 59
Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells. Molecular cancer therapeutics. 2009 Academic Article GET IT
Times cited: 17
Treatment of advanced thymoma and thymic carcinoma. Current treatment options in oncology. 2009 Review GET IT
Times cited: 37
An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 123
Update on Hsp90 inhibitors in clinical trial. Current topics in medicinal chemistry. 2009 Review GET IT
Times cited: 252
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. European journal of cancer (Oxford, England : 1990). 2008 Conference Paper GET IT
Times cited: 39
Comparative proteomics analysis of caspase-9-protein complexes in untreated and cytochrome c/dATP stimulated lysates of NSCLC cells. Journal of proteomics. 2008 Academic Article GET IT
Times cited: 20
Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients. British journal of cancer. 2008 Academic Article GET IT
Times cited: 40
Histone deacetylase inhibitors in cancer therapy. Current opinion in oncology. 2008 Review GET IT
Times cited: 106
Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. European journal of cancer (Oxford, England : 1990). 2008 Academic Article GET IT
Times cited: 36
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 120
Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. Journal of cancer research and clinical oncology. 2008 Academic Article GET IT
Times cited: 8
Newer opportunities in systemic therapy of lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Academic Article GET IT
Times cited: 6
Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Academic Article GET IT
Times cited: 51
Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 7
Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. European journal of nuclear medicine and molecular imaging. 2008 Academic Article GET IT
Times cited: 90
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Academic Article GET IT
Times cited: 87
Src as a potential therapeutic target in non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Review GET IT
Times cited: 73
Genotype analysis of the VNTR polymorphism in the SMYD3 histone methyltransferase gene: lack of correlation with the level of histone H3 methylation in NSCLC tissues or with the risk of NSCLC. International journal of cancer. 2008 Letter GET IT
Times cited: 6
Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PloS one. 2008 Academic Article GET IT
Times cited: 100
Antiangiogenic therapy in nonsmall cell lung cancer. Current opinion in oncology. 2008 Review GET IT
Times cited: 27
Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Review GET IT
Times cited: 284
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Molecular pharmacology. 2008 Academic Article GET IT
Times cited: 144
18Fluorodeoxyglucose positron emission tomography, a standard diagnostic tool in lung cancer. Journal of the National Cancer Institute. 2007 Editorial Article GET IT
Times cited: 4
The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells. Molecular cancer. 2007 Academic Article GET IT
Times cited: 24
Epidermal growth factor receptor (EGFR) gene copy number detection in non-small-cell lung cancer; a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization. Histopathology. 2007 Academic Article GET IT
Times cited: 26
Global histone modifications predict prognosis of resected non small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 236
Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). European journal of cancer (Oxford, England : 1990). 2007 Academic Article GET IT
Times cited: 72
Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain. Molecular cancer. 2007 Academic Article GET IT
Times cited: 20
Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). European journal of cancer (Oxford, England : 1990). 2007 Academic Article GET IT
Times cited: 54
Homodimerization antagonizes nuclear export of survivin. Traffic (Copenhagen, Denmark). 2007 Academic Article GET IT
Times cited: 40
A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 27
TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Molecular cancer therapeutics. 2007 Academic Article GET IT
Times cited: 106
A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 44
Advances at the Center for Cancer Research at the National Cancer Institute's Medical Oncology Branch. Clinical advances in hematology & oncology : H&O. 2007 Academic Article GET IT
Automated serum peptide profiling using novel magnetic C18 beads off-line coupled to MALDI-TOF-MS. Proteomics. Clinical applications. 2007 Academic Article GET IT
Times cited: 28
Immunohistochemical detection of nuclear survivin in NSCLC: a comparison of commercial antibodies. Histopathology. 2007 Letter GET IT
Times cited: 6
The potential of antiangiogenic therapy in non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Review GET IT
Times cited: 62
Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. Journal of the National Cancer Institute. 2007 Academic Article GET IT
Times cited: 602
Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460. Molecular cancer therapeutics. 2007 Academic Article GET IT
Times cited: 45
A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer. Anti-cancer drugs. 2007 Academic Article GET IT
Times cited: 46
Angiogenesis inhibitors. Drug selectivity and target specificity. Current pharmaceutical design. 2007 Review GET IT
Times cited: 40
Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor. Clinical & developmental immunology. 2007 Academic Article GET IT
Times cited: 24
EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens. Cellular oncology : the official journal of the International Society for Cellular Oncology. 2007 Academic Article GET IT
Times cited: 69
Genetic heterogeneity in patients with multiple neoplastic lung lesions: a report of three cases. 2007 GET IT
Times cited: 28
Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells: a small molecule Smac mimic sensitizes for chemotherapy-induced apoptosis by enhancing caspase-3 activation. Experimental cell research. 2006 Academic Article GET IT
Times cited: 41
Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Annals of oncology : official journal of the European Society for Medical Oncology. 2006 Academic Article GET IT
Times cited: 139
Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). European journal of cancer (Oxford, England : 1990). 2006 Academic Article GET IT
Times cited: 153
Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Molecular cancer therapeutics. 2006 Academic Article GET IT
Times cited: 108
Response to erlotinib in first-line treatment of non-small-cell lung cancer in a white male smoker with squamous-cell histology. 2006 GET IT
Times cited: 11
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2006 Conference Paper GET IT
Times cited: 26
The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. European radiology. 2006 Academic Article GET IT
Times cited: 69
The determination of gemcitabine and 2'-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2006 Academic Article GET IT
Times cited: 48
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 227
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 198
Iron absorption during epoetin alfa therapy for chemotherapy-associated anaemia. Cancer investigation. 2006 Academic Article GET IT
Times cited: 4
Biology and management of malignant pleural mesothelioma. European journal of cancer (Oxford, England : 1990). 2006 Review GET IT
Times cited: 56
Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Annals of oncology : official journal of the European Society for Medical Oncology. 2006 Academic Article GET IT
Times cited: 146
Systemic treatment of malignant thymoma: a decade experience at a single institution. American journal of clinical oncology. 2006 Academic Article GET IT
Times cited: 37
How should we analyse FDG PET studies for monitoring tumour response?. European journal of nuclear medicine and molecular imaging. 2006 Review GET IT
Times cited: 62
Quality assurance of thoracic radiotherapy in EORTC 08941: a randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy. European journal of cancer (Oxford, England : 1990). 2006 Academic Article GET IT
Times cited: 7
TUCAN/CARDINAL/CARD8 and apoptosis resistance in non-small cell lung cancer cells. BMC cancer. 2006 Academic Article GET IT
Times cited: 12
Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984). European journal of cancer (Oxford, England : 1990). 2006 Academic Article GET IT
Times cited: 19
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. 2006 GET IT
Times cited: 96
CT and MR imaging of neuroaxonal leukodystrophy presenting as early-onset frontal dementia. 2006 GET IT
Times cited: 22
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 200
Subcellular localization and nucleocytoplasmic transport of the chromosomal passenger proteins before nuclear envelope breakdown. Oncogene. 2006 Academic Article GET IT
Times cited: 29
Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 24
Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer. Cancer chemotherapy and pharmacology. 2006 Academic Article GET IT
Times cited: 14
Keynote comment: are large-scale cancer-genomics projects ready to use?. The Lancet. Oncology. 2006 Letter GET IT
Times cited: 1
Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data. The oncologist. 2006 Academic Article GET IT
Times cited: 6
Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level. The oncologist. 2006 Academic Article GET IT
Times cited: 18
Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 61
Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres. Molecular biology of the cell. 2006 Academic Article GET IT
Times cited: 66
Analysis of deoxycytidine accumulation in gemcitabine treated patients. Nucleosides, nucleotides & nucleic acids. 2006 Academic Article GET IT
Times cited: 3
Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. International journal of cancer. 2006 Academic Article GET IT
Times cited: 139
The expression of TUCAN, an inhibitor of apoptosis protein, in patients with advanced non-small cell lung cancer treated with chemotherapy. Anticancer research. 2006 Academic Article GET IT
Times cited: 5
Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies. International journal of cancer. 2005 Review GET IT
Times cited: 151
Introduction. Lung cancer (Amsterdam, Netherlands). 2005 Editorial Article GET IT
The role of EGFR-TK inhibition in non-small cell lung cancer. Onkologie. 2005 Editorial Article GET IT
Times cited: 1
Expression and localization of inhibitor of apoptosis proteins in normal human tissues. Human pathology. 2005 Academic Article GET IT
Times cited: 57
EGFR inhibitors in lung cancer. Oncology (Williston Park, N.Y.). 2005 Review GET IT
Times cited: 22
EGFR inhibitors: what have we learned from the treatment of lung cancer?. Nature clinical practice. Oncology. 2005 Review GET IT
Times cited: 76
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer. 2005 Review GET IT
Times cited: 150
Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Annals of oncology : official journal of the European Society for Medical Oncology. 2005 Academic Article GET IT
Times cited: 55
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 579
A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung cancer (Amsterdam, Netherlands). 2005 Academic Article GET IT
Times cited: 41
Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 194
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 547
Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 41
Morbidity and mortality in the surgery arm of EORTC 08941 trial. The European respiratory journal. 2005 Academic Article GET IT
Times cited: 76
Targeting HER1/EGFR in cancer therapy: experience with erlotinib. Future oncology (London, England). 2005 Review GET IT
Times cited: 18
Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2005 Academic Article GET IT
Times cited: 62
Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial. European journal of cancer (Oxford, England : 1990). 2005 Academic Article GET IT
Times cited: 40
Health economics: can we afford an unrestricted use of new biological agents in gastrointestinal oncology?. Current opinion in oncology. 2005 Review GET IT
Times cited: 25
Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours. Journal of clinical pathology. 2005 Academic Article GET IT
Times cited: 17
EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancer. Nature clinical practice. Oncology. 2005 Comment GET IT
Times cited: 15
Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Molecular pharmacology. 2005 Academic Article GET IT
Times cited: 104
Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Review GET IT
Times cited: 188
Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule. British journal of cancer. 2005 Academic Article GET IT
Times cited: 14
Cell death independent of caspases: a review. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Review GET IT
Times cited: 792
Identification of multiple nuclear export sequences in Fanconi anemia group A protein that contribute to CRM1-dependent nuclear export. Human molecular genetics. 2005 Academic Article GET IT
Times cited: 29
Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11. British journal of cancer. 2005 Academic Article GET IT
Times cited: 23
HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2005 Review GET IT
Times cited: 43
Treatment of malignant thymoma. Current opinion in oncology. 2005 Review GET IT
Times cited: 55
FANCD2 expression in advanced non-small-cell lung cancer and response to platinum-based chemotherapy. Clinical lung cancer. 2005 Academic Article GET IT
Times cited: 13
Lung cancer. Cancer chemotherapy and biological response modifiers. 2005 Review GET IT
Times cited: 1
Medical treatment of non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2005 Review GET IT
Times cited: 8
The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression. Oncogene. 2004 Academic Article GET IT
Times cited: 32
Gefitinib does not improve survival when combined with gemcitabine and cisplatin in people with advanced non-small-cell lung cancer. Cancer treatment reviews. 2004 Comment GET IT
Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2004 Academic Article GET IT
Times cited: 89
Nuclear shuttling and TRAF2-mediated retention in the cytoplasm regulate the subcellular localization of cIAP1 and cIAP2. Experimental cell research. 2004 Academic Article GET IT
Times cited: 34
Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma. Cancer research. 2004 Academic Article GET IT
Times cited: 63
Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA. Cancer gene therapy. 2004 Academic Article GET IT
Times cited: 33
Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL. British journal of cancer. 2004 Academic Article GET IT
Times cited: 29
The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clinical immunology (Orlando, Fla.). 2004 Review GET IT
Times cited: 107
Novel agents in the treatment of lung cancer: conference summary statement. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Conference Paper GET IT
Times cited: 26
The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 17
The role of gefitinib in lung cancer treatment. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Review GET IT
Times cited: 60
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology. 2004 Academic Article GET IT
Times cited: 49
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 1694
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 1673
Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group. European journal of cancer (Oxford, England : 1990). 2004 Academic Article GET IT
Times cited: 34
Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2004 Academic Article GET IT
Times cited: 18
Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2004 Academic Article GET IT
Times cited: 30
Cancer of the esophagus and gastric cardia: recent advances. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus. 2004 Review GET IT
Times cited: 60
Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells. Cancer research. 2004 Academic Article GET IT
Times cited: 189
Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver. Annals of oncology : official journal of the European Society for Medical Oncology. 2004 Academic Article GET IT
Times cited: 44
FOLFOX3 in heavily pretreated patients with metastatic colorectal cancer. The Netherlands journal of medicine. 2004 Academic Article GET IT
Times cited: 2
Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung cancer (Amsterdam, Netherlands). 2004 Academic Article GET IT
Times cited: 116
Twenty-five years of treating advanced NSCLC: what have we achieved?. Annals of oncology : official journal of the European Society for Medical Oncology. 2004 Academic Article GET IT
Times cited: 15
Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 351
Correspondence re: L. Yang et al., Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res., 63: 831-837, 2003. Cancer research. 2003 Letter GET IT
Times cited: 1
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. Journal of the National Cancer Institute. 2003 Academic Article GET IT
Times cited: 583
Lung cancer. Introduction. Lung cancer (Amsterdam, Netherlands). 2003 Academic Article GET IT
Times cited: 5
Ongoing and future trials of biologic therapies in lung cancer. Lung cancer (Amsterdam, Netherlands). 2003 Review GET IT
Times cited: 22
Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells. Cancer research. 2003 Academic Article GET IT
Times cited: 60
Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. an EORTC phase II study (EORTC 08958). European journal of cancer (Oxford, England : 1990). 2003 Academic Article GET IT
Times cited: 56
Subcellular localization of CrmA: identification of a novel leucine-rich nuclear export signal conserved in anti-apoptotic serpins. The Biochemical journal. 2003 Academic Article GET IT
Times cited: 14
Cisplatin triggers apoptotic or nonapoptotic cell death in Fanconi anemia lymphoblasts in a concentration-dependent manner. Experimental cell research. 2003 Academic Article GET IT
Times cited: 16
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 324
Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965). European journal of cancer (Oxford, England : 1990). 2003 Academic Article GET IT
Times cited: 101
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 2876
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. Cancer chemotherapy and pharmacology. 2003 Academic Article GET IT
Times cited: 46
[Novel approaches; improved diagnosis and therapy with DNA microarrays. I. Technology and data analysis]. Nederlands tijdschrift voor geneeskunde. 2003 Comment GET IT
Times cited: 7
[Novel approaches; improved diagnostics and therapeutics with DNA microarrays. II. Applications]. Nederlands tijdschrift voor geneeskunde. 2003 Review GET IT
Times cited: 4
Correspondence re: C. G. Ferreira et al., Apoptosis: target of cancer therapy. Clin. Cancer Res., 8: 2024-2034, 2002. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Letter GET IT
Times cited: 4
Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923). Annals of oncology : official journal of the European Society for Medical Oncology. 2003 Academic Article GET IT
Times cited: 23
The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). European journal of cancer (Oxford, England : 1990). 2003 Academic Article GET IT
Times cited: 57
European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 69
Lung cancer. Cancer chemotherapy and biological response modifiers. 2003 Review GET IT
Times cited: 5
Signal transduction modulators for cancer therapy: from promise to practice? 2003 GET IT
Times cited: 4
Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. The oncologist. 2003 Review GET IT
Times cited: 64
The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs of today (Barcelona, Spain : 1998). 2003 Review GET IT
Times cited: 84
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 474
Phase II trial of ZD0473 as second-line therapy in mesothelioma. European journal of cancer (Oxford, England : 1990). 2002 Academic Article GET IT
Times cited: 52
The role of new agents in the treatment of non-small cell lung cancer. European journal of cancer (Oxford, England : 1990). 2002 Review GET IT
Times cited: 30
Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 238
Targeted therapy in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2002 Review GET IT
Times cited: 13
Clinical impact of novel treatment strategies. Oncogene. 2002 Review GET IT
Times cited: 48
Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 98
Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. 2002 GET IT
Times cited: 177
Natural Killer T cells. The Lancet. Oncology. 2002 Academic Article GET IT
Times cited: 8
Late activation of apoptotic pathways plays a negligible role in mediating the cytotoxic effects of discodermolide and epothilone B in non-small cell lung cancer cells. Cancer research. 2002 Academic Article GET IT
Times cited: 53
Apoptosis: target of cancer therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Review GET IT
Times cited: 258
Endothelial dysfunction in antiangiogenesis-associated thrombosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Letter GET IT
Early results of a randomized phase III trial of platinum-containing doublets versus a nonplatinum doublet in the treatment of advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer 08975. Seminars in oncology. 2002 Academic Article GET IT
Times cited: 18
Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. European journal of cancer (Oxford, England : 1990). 2002 Academic Article GET IT
Times cited: 70
A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma. British journal of cancer. 2002 Academic Article GET IT
Times cited: 20
CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. Experimental cell research. 2002 Academic Article GET IT
Times cited: 144
A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma. European journal of cancer (Oxford, England : 1990). 2002 Academic Article GET IT
Times cited: 28
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 261
Overview of past, present and future of the EORTC Lung Cancer Group. European Organisation for Research and Treatment of Cancer. European journal of cancer (Oxford, England : 1990). 2002 Academic Article GET IT
Times cited: 2
Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 65
Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 113
Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. Journal of immunology (Baltimore, Md. : 1950). 2002 Academic Article GET IT
Times cited: 145
Population pharmacokinetics of the novel anticancer agent KRN7000. Cancer chemotherapy and pharmacology. 2002 Academic Article GET IT
Times cited: 32
Novel approaches to the treatment of non-small cell lung cancer. Critical reviews in oncology/hematology. 2002 Review GET IT
Times cited: 36
Pleura mesothelioma: combined modality treatments. Annals of oncology : official journal of the European Society for Medical Oncology. 2002 Review GET IT
Times cited: 7
Update on the systemic treatment of lung cancer. Cancer chemotherapy and biological response modifiers. 2002 Review GET IT
Exercise-induced spontaneous hemothorax insinuates trauma; yet unmasks a lament disorder. 2001 GET IT
Times cited: 3
Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy. British journal of cancer. 2001 Academic Article GET IT
Times cited: 14
Fluorouracil (5FU) pharmacokinetics in 5FU prodrug formulations with a dihydropyrimidine dehydrogenase inhibitor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Letter GET IT
Times cited: 11
A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2001 Academic Article GET IT
Times cited: 6
Chemotherapy for non-small-cell lung cancer. Lancet (London, England). 2001 Letter GET IT
Times cited: 1
Chemotherapy for non-small-cell lung cancer. Lancet (London, England). 2001 Letter GET IT
Times cited: 5
Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Annals of oncology : official journal of the European Society for Medical Oncology. 2001 Academic Article GET IT
Times cited: 93
State of the art in systemic treatment of lung cancer. European journal of cancer (Oxford, England : 1990). 2001 Review GET IT
Times cited: 4
Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clinical immunology (Orlando, Fla.). 2001 Academic Article GET IT
Times cited: 247
Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001 Academic Article GET IT
Times cited: 135
Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2001 Academic Article GET IT
Times cited: 100
[Decline in the need for blood transfusions in cancer patients due to the use of epoietin alfa during cisplatin based chemotherapy]. Nederlands tijdschrift voor geneeskunde. 2001 Academic Article GET IT
Times cited: 5
Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2001 Academic Article GET IT
Times cited: 52
5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2001 Academic Article GET IT
Times cited: 61
Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling. Lung cancer (Amsterdam, Netherlands). 2001 Academic Article GET IT
Times cited: 10
Lung cancer. Cancer chemotherapy and biological response modifiers. 2001 Review GET IT
Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. Journal of immunological methods. 2001 Academic Article GET IT
Times cited: 89
Thymoma: update for the new millennium. The oncologist. 2001 Review GET IT
Times cited: 76
Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer research. 2000 Academic Article GET IT
Times cited: 188
Hepatic arterial 5-fluorouracil in patients with liver metastases of colorectal cancer: single-centre experience in 145 patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2000 Academic Article GET IT
Times cited: 21
Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours. European journal of cancer (Oxford, England : 1990). 2000 Academic Article GET IT
Times cited: 28
[Clinical thinking and decision making in practice. A patient with anal cancer and hypercalcemia]. 2000 GET IT
Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Review GET IT
Times cited: 122
Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients. Anti-cancer drugs. 2000 Academic Article GET IT
Times cited: 10
Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. European journal of cancer (Oxford, England : 1990). 2000 Academic Article GET IT
Times cited: 43
Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. British journal of cancer. 2000 Academic Article GET IT
Times cited: 74
Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 207
Dexrazoxane in anthracycline extravasation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Letter GET IT
Times cited: 48
Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver. Oncology. 2000 Review GET IT
Times cited: 12
Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2000 Academic Article GET IT
Times cited: 54
Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 168
Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 143
A bone biopsy is mandatory in the optimal management of bone lesions in patients with a long-term history of malignancy of the breast. 2000 GET IT
Times cited: 2
Caelyx in malignant mesothelioma: a phase II EORTC study. Annals of oncology : official journal of the European Society for Medical Oncology. 2000 Academic Article GET IT
Times cited: 58
Severe acute lung injury induced by gemcitabine. 2000 GET IT
Times cited: 41
Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Annals of oncology : official journal of the European Society for Medical Oncology. 2000 Review GET IT
Times cited: 147
Human natural killer T cells acquire a memory-activated phenotype before birth. Blood. 2000 Academic Article GET IT
Times cited: 99
Synergistic effect of KRN7000 with interleukin-15, -7, and -2 on the expansion of human V alpha 24+V beta 11+ T cells in vitro. Human immunology. 2000 Academic Article GET IT
Times cited: 29
A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2000 Academic Article GET IT
Times cited: 39
Clinical perspectives on platinum resistance. Drugs. 2000 Review GET IT
Times cited: 304
Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Academic Article GET IT
Times cited: 87
The multilayered postconfluent cell culture as a model for drug screening. Critical reviews in oncology/hematology. 2000 Review GET IT
Times cited: 78
Treatment of thymoma and thymic carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2000 Review GET IT
Times cited: 9
Validation of a polymerase chain reaction aided transcript titration assay (PATTY) for topoisomerase II in lung cancer samples. Anticancer research. 2000 Academic Article GET IT
10th Conference on DNA Topoisomerases in therapy. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 1999 Academic Article GET IT
Times cited: 2
Effects of alpha-galactosylceramide (KRN7000), interleukin-12 and interleukin-7 on phenotype and cytokine profile of human Valpha24+ Vbeta11+ T cells. Immunology. 1999 Academic Article GET IT
Times cited: 35
p53 and chemosensitivity. Annals of oncology : official journal of the European Society for Medical Oncology. 1999 Review GET IT
Times cited: 154
Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999 Academic Article GET IT
Times cited: 105
Second-line chemotherapy and its evaluation in small cell lung cancer. Cancer treatment reviews. 1999 Review GET IT
Times cited: 57
Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 138
The cost-effectiveness of paclitaxel (Taxol) + cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer: a multicountry analysis. Anti-cancer drugs. 1999 Academic Article GET IT
Times cited: 21
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer. 1999 Academic Article GET IT
Times cited: 127
Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. European journal of cancer (Oxford, England : 1990). 1999 Academic Article GET IT
Times cited: 133
Chemotherapy of advanced non-small-cell lung cancer: "Those who cannot remember the past are condemned to repeat it". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Letter GET IT
Gemcitabine plus taxane combinations in non-small cell lung cancer. Seminars in oncology. 1999 Review GET IT
Times cited: 5
A PCR-aided transcript titration assay (PATTY) to measure topoisomerase I gene expression in human tumor specimens. Anticancer research. 1999 Academic Article GET IT
Times cited: 6
Current chemotherapeutic possibilities in pancreaticobiliary cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 1999 Review GET IT
Times cited: 29
DNA topoisomerase II poisons and inhibitors. Cancer chemotherapy and biological response modifiers. 1999 Review GET IT
Times cited: 21
Pancreaticobiliary cancer: the future aspects of medical oncology. Annals of oncology : official journal of the European Society for Medical Oncology. 1999 Review GET IT
Times cited: 16
Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer. The oncologist. 1999 Academic Article GET IT
Times cited: 37
Are platinum compounds mandatory in the treatment of metastatic non-small cell lung cancer?. European journal of cancer (Oxford, England : 1990). 1998 Review GET IT
Times cited: 10
Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening. British journal of cancer. 1998 Academic Article GET IT
Times cited: 8
Clinical resistance to topoisomerase-targeted drugs. Biochimica et biophysica acta. 1998 Review GET IT
Times cited: 49
Radiotherapy with/without cisplatin following chemotherapy in limited small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Letter GET IT
Times cited: 1
An update on European randomized studies in non-small cell lung cancer. Seminars in oncology. 1998 Review GET IT
Times cited: 8
Gemcitabine and paclitaxel combinations in non-small cell lung cancer. Seminars in oncology. 1998 Review GET IT
Times cited: 11
Determinants of CPT-11 and SN-38 activities in human lung cancer cells. British journal of cancer. 1998 Academic Article GET IT
Times cited: 86
Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
Times cited: 270
Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. British journal of cancer. 1998 Academic Article GET IT
Times cited: 172
Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 1998 Academic Article GET IT
Times cited: 96
CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. British journal of cancer. 1998 Academic Article GET IT
Times cited: 55
Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens. Clinical drug investigation. 1998 Academic Article GET IT
Times cited: 13
Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncology reports. 1998 Academic Article GET IT
Times cited: 41
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Review GET IT
Times cited: 459
Clinical trials report on ongoing trials in lung cancer. Expert opinion on investigational drugs. 1997 Academic Article GET IT
A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 1997 Academic Article GET IT
Times cited: 88
Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group. European journal of cancer (Oxford, England : 1990). 1997 Academic Article GET IT
Times cited: 48
Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 1997 Academic Article GET IT
Times cited: 13
Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. European journal of cancer (Oxford, England : 1990). 1997 Academic Article GET IT
Times cited: 57
Detection of cytokeratin-19 transcripts by reverse transcriptase-polymerase chain reaction in lung cancer cell lines and blood of lung cancer patients. Laboratory investigation; a journal of technical methods and pathology. 1997 Academic Article GET IT
Times cited: 74
Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
Times cited: 121
FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer research. 1997 Academic Article GET IT
Times cited: 209
Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
Times cited: 162
Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. International journal of cancer. 1997 Academic Article GET IT
Times cited: 103
Chemotherapy. Lancet (London, England). 1997 Review GET IT
Times cited: 16
Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
Times cited: 431
Cisplatin/paclitaxel vs cisplatin/teniposide for advanced non-small-cell lung cancer. The EORTC Lung Cancer Cooperative Group. The European Organization for Research and Treatment of Cancer. Oncology (Williston Park, N.Y.). 1997 Academic Article GET IT
Times cited: 5
Clinical pharmacology of carboplatin administered in combination with paclitaxel. Seminars in oncology. 1997 Academic Article GET IT
Times cited: 37
CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. International journal of cancer. 1997 Academic Article GET IT
Times cited: 113
DNA topoisomerase II poisons and inhibitors. Cancer chemotherapy and biological response modifiers. 1997 Review GET IT
Times cited: 11
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
Times cited: 184
Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer. EORTC Lung Cancer Cooperative Group. Seminars in oncology. 1996 Academic Article GET IT
Times cited: 11
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. British journal of cancer. 1996 Academic Article GET IT
Times cited: 78
Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues. Annals of oncology : official journal of the European Society for Medical Oncology. 1996 Academic Article GET IT
Times cited: 51
Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: a randomized phase II trial of the EORTC lung cancer cooperative group. Annals of oncology : official journal of the European Society for Medical Oncology. 1996 Academic Article GET IT
Times cited: 8
Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial. European journal of cancer (Oxford, England : 1990). 1996 Academic Article GET IT
Times cited: 32
p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. British journal of cancer. 1996 Academic Article GET IT
Times cited: 94
MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs. International journal of cancer. 1996 Academic Article GET IT
Times cited: 60
[Role of chemotherapy in non-small cell lung carcinoma]. Nederlands tijdschrift voor geneeskunde. 1996 Review GET IT
Times cited: 2
New drugs for the management of lung cancer. British journal of hospital medicine. 1996 Review GET IT
Times cited: 8
Oncogenes and antioncogenes in lung tumorigenesis. Chest. 1996 Review GET IT
Times cited: 39
Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. The American journal of pathology. 1996 Academic Article GET IT
Times cited: 198
Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Academic Article GET IT
Times cited: 192
Treatment of metastatic non-small cell lung cancer. Current opinion in oncology. 1996 Academic Article GET IT
Times cited: 23
A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer. An EORTC Lung Cancer Cooperative Group trial. Annals of oncology : official journal of the European Society for Medical Oncology. 1996 Academic Article GET IT
Times cited: 33
Ongoing clinical trials in lung cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 1996 Review GET IT
Times cited: 1
DNA topoisomerase inhibitors. Cancer chemotherapy and biological response modifiers. 1996 Review GET IT
Times cited: 4
Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology. 1996 Academic Article GET IT
Times cited: 13
Drug Resistance. The oncologist. 1996 Academic Article GET IT
Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Academic Article GET IT
Times cited: 23
Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Biochimica et biophysica acta. 1995 Academic Article GET IT
Times cited: 76
P-glycoprotein--a marker of cancer-cell behavior. The New England journal of medicine. 1995 Editorial Article GET IT
Times cited: 91
Differential expression of the c-kit proto-oncogene in germ cell tumours. The Journal of pathology. 1995 Academic Article GET IT
Times cited: 129
Multidrug resistance proteins and other drug transport-related resistance to natural product agents. Current opinion in oncology. 1995 Review GET IT
Times cited: 80
DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?. British journal of cancer. 1995 Academic Article GET IT
Times cited: 66
Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia. Leukemia. 1995 Academic Article GET IT
Times cited: 27
Prognostic relevance of P-glycoprotein expression in breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 1995 Academic Article GET IT
Times cited: 84
Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. Journal of the National Cancer Institute. 1995 Academic Article GET IT
Times cited: 233
Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer. Seminars in oncology. 1995 Academic Article GET IT
Times cited: 30
MRP gene overexpression in a human doxorubicin-resistant SCLC cell line: alterations in cellular pharmacokinetics and in pattern of cross-resistance. International journal of cancer. 1995 Academic Article GET IT
Times cited: 44
New drugs in non-small cell lung cancer. An overview. Lung cancer (Amsterdam, Netherlands). 1995 Review GET IT
Times cited: 17
Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 65
Effects of suramin on human lung cancer cell lines. European journal of cancer (Oxford, England : 1990). 1995 Academic Article GET IT
Times cited: 15
MDR1/P-glycoprotein expression in colorectal cancer. European journal of cancer (Oxford, England : 1990). 1995 Review GET IT
Times cited: 55
Multidrug resistance in breast cancer: mechanisms, strategies. European journal of cancer (Oxford, England : 1990). 1995 Review GET IT
Times cited: 15
A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest. 1994 Academic Article GET IT
Times cited: 301
Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol). Seminars in oncology. 1994 Review GET IT
Times cited: 48
Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort. Seminars in oncology. 1994 Academic Article GET IT
Times cited: 15
Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures. Biochemical pharmacology. 1994 Academic Article GET IT
Times cited: 15
Complete remission of metastatic colorectal cancer: a pitfall in a multidrug resistance reversal trial. Lancet (London, England). 1994 Letter GET IT
Times cited: 2
Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression. Biochemical pharmacology. 1994 Academic Article GET IT
Times cited: 37
Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994 Academic Article GET IT
Times cited: 42
DNA topoisomerases and topoisomerase inhibitors. Pathologie-biologie. 1994 Review GET IT
Times cited: 28
In-vitro schedule-dependency of eo9 and miltefosine in comparison to standard drugs in colon-cancer cells. International journal of oncology. 1994 Academic Article GET IT
Times cited: 10
DNA topoisomerase inhibitors. Cancer chemotherapy and biological response modifiers. 1994 Review GET IT
Times cited: 5
In vitro sequence-dependent synergistic effect of suramin and camptothecin. European journal of cancer (Oxford, England : 1990). 1994 Academic Article GET IT
Times cited: 7
Small cell lung cancer and topoisomerases. Anticancer research. 1994 Review GET IT
Times cited: 7
Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 141
Antiemetic activity of oral lorazepam in addition to methylprednisolone and metoclopramide in the prophylactic treatment of vomiting induced by cisplatin. A double-blind, placebo-controlled study with crossover design. Tumori. 1993 Academic Article GET IT
Times cited: 7
Cortisol is transported by the multidrug resistance gene product P-glycoprotein. British journal of cancer. 1993 Academic Article GET IT
Times cited: 133
Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures. European journal of cancer (Oxford, England : 1990). 1993 Academic Article GET IT
Times cited: 35
DNA topoisomerase inhibitors. Cancer chemotherapy and biological response modifiers. 1993 Review GET IT
Times cited: 3
Characterization of a topoisomerase II gene rearrangement in a human small-cell lung cancer cell line. Journal of the National Cancer Institute. 1992 Academic Article GET IT
Times cited: 18
Multidrug resistance gene (P-glycoprotein) expression in the human fetus. The American journal of pathology. 1992 Academic Article GET IT
Times cited: 123
Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates. British journal of cancer. 1992 Academic Article GET IT
Times cited: 33
Increased expression of differentiation markers can accompany laminin-induced attachment of small cell lung cancer cells. British journal of cancer. 1992 Academic Article GET IT
Times cited: 8
Views and news from Melbourne, the Sixth World Conference on Lung Cancer. The EORTC Lung Cancer Co-operative Group. The European respiratory journal. 1992 Conference Paper GET IT
The differential diagnosis of primary lung cancer: inter-observer agreement and contribution of specific diagnostic procedures. Journal of clinical epidemiology. 1992 Academic Article GET IT
Times cited: 5
Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1992 Academic Article GET IT
Times cited: 60
Neuromedin B is present in lung cancer cell lines. Cancer research. 1992 Academic Article GET IT
Times cited: 85
Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer research. 1992 Academic Article GET IT
Times cited: 133
Teniposide alone and in combination chemotherapy in small cell lung cancer. Seminars in oncology. 1992 Review GET IT
Times cited: 8
The European Organization for Research and Treatment of Cancer experience with teniposide: preliminary results of a randomized study in non-small cell lung cancer. Seminars in oncology. 1992 Academic Article GET IT
Times cited: 5
Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. Journal of the National Cancer Institute. Monographs. 1992 Academic Article GET IT
Times cited: 38
Comparison of two carboplatin-containing regimens with standard chemotherapy for small cell lung cancer in a randomised phase II study. The EORTC Lung Cancer Cooperative group. European journal of cancer (Oxford, England : 1990). 1992 Academic Article GET IT
Times cited: 12
Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC Lung Cancer Cooperative Group. European journal of cancer (Oxford, England : 1990). 1992 Academic Article GET IT
Times cited: 18
In vitro chemosensitivity testing of multilayered microcultures. Anticancer research. 1992 Academic Article GET IT
Times cited: 4
Phase II study of ACNU as second-line treatment in small-cell lung cancer. EORTC Lung Cancer Cooperative Group. Cancer chemotherapy and pharmacology. 1992 Academic Article GET IT
Times cited: 7
Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991 Academic Article GET IT
Times cited: 61
Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients. European journal of cancer (Oxford, England : 1990). 1991 Academic Article GET IT
Times cited: 34
Cisplatin and teniposide chemotherapy for advanced non-small cell lung cancer. European journal of cancer (Oxford, England : 1990). 1991 Academic Article GET IT
Times cited: 3
Mitomycin C, teniposide, and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Cancer chemotherapy and pharmacology. 1991 Academic Article GET IT
Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. European journal of cancer (Oxford, England : 1990). 1991 Academic Article GET IT
Times cited: 45
Multidrug resistance from the clinical point of view. European journal of cancer (Oxford, England : 1990). 1991 Review GET IT
Times cited: 46
Multimodality treatment of malignant germ cell tumours of the mediastinum. European journal of cancer (Oxford, England : 1990). 1991 Academic Article GET IT
Times cited: 18
Phase II study of ACNU in non-small-cell lung cancer: EORTC study 08872. Cancer chemotherapy and pharmacology. 1991 Academic Article GET IT
Times cited: 5
Pilot study of teniposide in combination chemotherapy for small cell lung cancer. European journal of cancer (Oxford, England : 1990). 1991 Academic Article GET IT
Times cited: 2
4'-EPI-doxorubicin in advanced lung cancer. A phase II trial. Investigational new drugs. 1990 Academic Article GET IT
Times cited: 7
Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proceedings of the National Academy of Sciences of the United States of America. 1990 Academic Article GET IT
Times cited: 225
Effects of tumor necrosis factor, alone or in combination with topoisomerase-II-targeted drugs, on human lung cancer cell lines. International journal of cancer. 1990 Academic Article GET IT
Times cited: 12
Doxorubicin and etoposide in the treatment of advanced measurable breast cancer. Oncology. 1990 Academic Article GET IT
Times cited: 2
[Piperacillin and amikacin in the treatment of infections in neoplasm patients with granulocytopenia]. La Clinica terapeutica. 1989 Academic Article GET IT
Phase II study of divided-dose vinblastine in advanced cancer patients. Tumori. 1989 Academic Article GET IT
Times cited: 2
Phase II study of 9-hydroxy-2-methyl-ellipticinium acetate (ellipticinium) in patients with advanced carcinoma of the lung. EORTC Lung Cancer Cooperative Group. European journal of cancer & clinical oncology. 1989 Academic Article GET IT
Times cited: 12
Isolated central nervous system metastasis from ovarian carcinoma: a case report. 1989 GET IT
Times cited: 6
Identification of new drugs in pretreated patients with small cell lung cancer. European journal of cancer & clinical oncology. 1989 Academic Article GET IT
Times cited: 17
Lonidamine versus polychemotherapy in advanced non-small-cell lung cancer. A preliminary analysis. Tumori. 1989 Academic Article GET IT
Times cited: 6
Phase II study of alpha-interferon plus bleomycin in advanced non-small cell lung cancer. Anticancer research. 1989 Academic Article GET IT
Times cited: 1
Phase II study of esorubicin in the treatment of patients with advanced sarcoma. Oncology. 1989 Academic Article GET IT
Times cited: 5
The European Organization for Research and Treatment of Cancer (EORTC) trials of new agents for advanced non-small cell lung cancer. Seminars in oncology. 1988 Academic Article GET IT
Times cited: 3
Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1988 Academic Article GET IT
Times cited: 123
Scalp hypothermia in the prevention of doxorubicin-induced hair loss. Cancer nursing. 1988 Academic Article GET IT
Times cited: 36
Carboplatin (JM 8), adriamycin and cyclophosphamide (JAC) in advanced ovarian carcinoma: a pilot study. Tumori. 1988 Academic Article GET IT
Times cited: 4
Cisplatin and etoposide in chemotherapy-refractory advanced breast cancer. Tumori. 1988 Academic Article GET IT
Times cited: 12
Teniposide (VM26): an effective treatment for brain metastases of small cell carcinoma of the lung. European journal of cancer & clinical oncology. 1988 Academic Article GET IT
Times cited: 31
High doses of methylprednisolone with or without alizapride in the prevention of cisplatin-induced emesis. A randomized, double-blind, crossover study. Oncology. 1988 Academic Article GET IT
Times cited: 3
Inverted urothelial papilloma: a lesion with malignant potential. 1988 GET IT
Times cited: 32
Phase II study of divided-dose vinblastine in advanced breast cancer patients. Cancer chemotherapy and pharmacology. 1988 Academic Article GET IT
Times cited: 3
Reinduction chemotherapy in small cell lung cancer. European journal of cancer & clinical oncology. 1987 Academic Article GET IT
Times cited: 107
Mitomycin C, vinblastine and cis-platin. An active regimen for advanced non-small cell lung cancer. British journal of cancer. 1987 Academic Article GET IT
Times cited: 13
4'-Deoxydoxorubicin, an inactive drug in small cell lung cancer. European journal of cancer & clinical oncology. 1987 Academic Article GET IT
Times cited: 4
Bone marrow evaluation in small cell carcinoma of the lung. Acta oncologica (Stockholm, Sweden). 1987 Academic Article GET IT
Times cited: 9
Teniposide in the treatment of non-small cell lung carcinoma. Cancer treatment reports. 1987 Academic Article GET IT
Times cited: 19
[Monitoring of neuron specific enolase (NSE) in patients with a diagnosis of pulmonary microcytoma. Preliminary results]. Giornale italiano di oncologia. 1987 Academic Article GET IT
Long-term survival and complete response to adriamycin and etoposide in a case of hepatocellular carcinoma. 1986 GET IT
Thymomas. A review of 169 cases, with particular reference to results of surgical treatment. Cancer. 1986 Academic Article GET IT
Times cited: 141
Stevens-Johnson syndrome and fatal pulmonary toxicity to combination chemotherapy containing bleomycin: a case report. 1986 GET IT
Times cited: 10
In vitro evaluation of myelotoxicity induced by antineoplastic drugs. Chemioterapia : international journal of the Mediterranean Society of Chemotherapy. 1986 Academic Article GET IT
Cisplatin-containing chemotherapy in the treatment of invasive thymoma: report of five cases. Cancer treatment reports. 1985 Academic Article GET IT
Times cited: 24
Disorders of serum electrolytes and renal function in patients treated with cis-platinum on an outpatient basis. European journal of cancer & clinical oncology. 1985 Academic Article GET IT
Times cited: 18
High dose cisplatin after failure of polychemotherapy containing cisplatin in ovarian cancer. Preliminary results. Chemioterapia : international journal of the Mediterranean Society of Chemotherapy. 1985 Academic Article GET IT
Chest irradiation as an attempt to improve the response after induction chemotherapy in small cell lung carcinoma. Acta radiologica. Oncology. 1985 Academic Article GET IT
Times cited: 1
Two sudden deaths during prophylactic antiemetic treatment with high doses of domperidone and methylprednisolone. Lancet (London, England). 1984 Letter GET IT
Times cited: 41
Comparison of methylprednisolone and metoclopramide in the prophylactic treatment of cis-platin-induced nausea and vomiting. Tumori. 1984 Academic Article GET IT
Times cited: 4
[Chemotherapy in advanced forms of carcinoma of the ovary]. Minerva ginecologica. 1984 Academic Article GET IT
[Chemotherapy of a second instance of carcinoma of the ovary]. Minerva ginecologica. 1984 Academic Article GET IT
[Staging of malignant tumors of the ovary. Observations on the lack of diagnostic procedures. review of 141 cases]. Minerva ginecologica. 1984 Academic Article GET IT
Father-son testicular cancer, case report. 1983 GET IT
Times cited: 6
Combination chemotherapy for metastatic brain tumors. Tumori. 1981 Academic Article GET IT
Times cited: 5

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

DEVELOPMENT OF NEW MODELS OF THYMIC EPITHELIAL TUMORS awarded by Thymic Carcinoma Center Principal Investigator 2022 - 2023

more ...

less ...

Background

education and training

Ph.D., Vrije University, Amsterdam (Netherlands) 1995
M.D., University of Turin Faculty of Medicine and Surgery (Italy) 1980

Contact

full name

Giuseppe Giaccone

primary email

gig4001@med.cornell.edu

VIVO Weill Cornell Medical College

Giuseppe Giaccone Professor of Medicine (Courtesy)

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email